| Recruiting | [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications NCT07432633 | Blue Earth Diagnostics | Phase 1 / Phase 2 |
| Recruiting | Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) NCT07480954 | Beijing Biotech | Phase 1 / Phase 2 |
| Recruiting | A Study of Isoquercetin in People With Ovarian Cancer NCT07303894 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Recruiting | AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant O NCT07218809 | AstraZeneca | Phase 3 |
| Recruiting | A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine NCT06890338 | AbbVie | Phase 2 |
| Recruiting | Single-arm, Prospective Clinical Trial of Efficacy and Safety of Daphnetin Capsules Combined With TC Regimen f NCT07495397 | The First Hospital of Jilin University | N/A |
| Recruiting | Prehabilitation for EOC, Fallopian Tube, Primary Peritoneal Carcinoma and Pancreatic Cancer w/ NACT NCT06412510 | Case Comprehensive Cancer Center | Phase 1 / Phase 2 |
| Recruiting | A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant NCT06994195 | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 3 |
| Recruiting | Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adju NCT06915025 | Imunon | Phase 3 |
| Not Yet Recruiting | EPITOME-1015-I: a Study to Investigate the Safety and Tolerability of MDG1015 in Patients with Epithelial Ovar NCT06748872 | Medigene AG | Phase 1 |
| Not Yet Recruiting | Surgery for Relapsed Ovarian Cancer in Precision NCT06602063 | Shanghai Gynecologic Oncology Group | Phase 1 / Phase 2 |
| Active Not Recruiting | Centralization and Oncologic Outcomes in Ovarian Cancer NCT07075939 | Azienda USL Reggio Emilia - IRCCS | — |
| Withdrawn | A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Vari NCT04889495 | Pfizer | — |
| Recruiting | CT-95 in Advanced Cancers Associated With Mesothelin Expression NCT06756035 | Context Therapeutics Inc. | Phase 1 |
| Not Yet Recruiting | The Application of Sentinel Lymph Node Mapping Technique in the Surgery of Early Epithelial Ovarian Cancer NCT06673511 | Anhui Provincial Hospital | N/A |
| Recruiting | CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer. NCT06690775 | TORL Biotherapeutics, LLC | Phase 2 |
| Not Yet Recruiting | Fluzoparib in Combination With Apatinib Mesylate for Maintenance Therapy in Stage III-IV Ovarian Cancer NCT06539091 | Anhui Provincial Hospital | Phase 3 |
| Recruiting | A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in NCT06469281 | Regeneron Pharmaceuticals | Phase 1 |
| Recruiting | Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells NCT06305299 | UNC Lineberger Comprehensive Cancer Center | Phase 1 |
| Recruiting | Fasting During Neoadjuvant Chemotherapy in Patient With Epithelial Ovarian Cancer NCT06386887 | Case Comprehensive Cancer Center | N/A |
| Recruiting | Cukurova Score Validation Study NCT06378905 | Cukurova University | — |
| Recruiting | A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies NCT06395519 | 858 Therapeutics, Inc. | Phase 1 / Phase 2 |
| Not Yet Recruiting | To Explore the Feasibility of Dynamic Changes of TCR Diversity in Peripheral Blood in Monitoring Recurrence an NCT06315270 | The First Hospital of Jilin University | — |
| Unknown | Administration of Hyperthermic Intraperitoneal Chemotherapy in the General Ward NCT06277947 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | N/A |
| Completed | RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal NCT06173037 | RemeGen Co., Ltd. | Phase 2 |
| Recruiting | Application of MRD Combined With Personalized Vaccine in the Treatment of Postoperative Recurrence Prevention NCT06341907 | Second Affiliated Hospital of Wenzhou Medical University | Phase 2 / Phase 3 |
| Unknown | SUROVA - Surgery in Ovarian Cancer, Comparing Primary and Interval Cytoreductive Surgery NCT06223763 | Clinica Universidad de Navarra, Universidad de Navarra | — |
| Not Yet Recruiting | Health-Economic Evaluation of Early Diagnosis of Epithalial Ovarian Cancer Recurrence Using the ROMA Score: a NCT05991752 | University Hospital, Tours | N/A |
| Not Yet Recruiting | A Prospective, Randomized Controlled Study of Cyclophosphamide, Bevacizumab With or Without Envafolimab in Rec NCT06010667 | Hebei Medical University Fourth Hospital | — |
| Recruiting | Study of AVZO-021 in Patients With Advanced Solid Tumors NCT05867251 | Avenzo Therapeutics, Inc. | Phase 1 / Phase 2 |
| Terminated | REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Cho NCT05870748 | Sutro Biopharma, Inc. | Phase 2 / Phase 3 |
| Terminated | 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors NCT05563272 | Telix Pharmaceuticals (Innovations) Pty Ltd | Phase 2 |
| Recruiting | Prognostic and Diagnostic Added Value of Medical Imaging in Gynecological Cancer (PRODIGYN) NCT05855941 | Region Västerbotten | — |
| Unknown | Clinical Application of 68Ga-FAPI PET Imaging in Detection of Ovarian Cancer Recurrence NCT05856409 | RenJi Hospital | — |
| Unknown | Effect of Sodium Thiosulfate on Nephrotoxicity of Cisplatin Intraperitoneal Heat-perfusion Chemotherapy NCT05877911 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 2 |
| Completed | A Study to Evaluate the Safety of KAND567, in Combination With Carboplatin Therapy, in Women With Recurrent Ep NCT06087289 | Novakand Pharma AB | Phase 1 / Phase 2 |
| Terminated | Association of Ex Vivo Drug Response (EVDR) and Clinical Outcome in Ovarian Cancer NCT06068738 | Exscientia AI Limited | — |
| Unknown | ctDNA Methylation for Detecting Ovarian Cancer NCT05801276 | Lei Li | — |
| Unknown | ctDNA Methylation for Epithelial Ovarian Cancer NCT05801263 | Lei Li | — |
| Recruiting | NEOadjuvant Dendritic Cell Vaccination for Ovarian Cancer NCT05773859 | Radboud University Medical Center | Phase 1 / Phase 2 |
| Terminated | A Phase 1 Safety, Tolerability, and Pharmacokinetics Study of AMG 794 With Claudin 6-positive Non-small Cell L NCT05317078 | Amgen | Phase 1 |
| Recruiting | The Immune Landscape of Epithelial Ovarian Cancer NCT05984875 | Oncology Institute of Southern Switzerland | — |
| Active Not Recruiting | Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer NCT05620134 | Salubris Biotherapeutics Inc | Phase 1 / Phase 2 |
| Unknown | Predicting the Risk of Ovarian Cancer Recurrence Using Circulating Tumor DNA to Assess Residual Disease NCT05212779 | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) | — |
| Recruiting | T-regulatory Cell Depletion with E7777 Combined with Pembrolizumab in Recurrent or Metastatic Solid Tumors NCT05200559 | Alexander B Olawaiye, MD | Phase 1 / Phase 2 |
| Terminated | ITIL-306 in Advanced Solid Tumors NCT05397093 | Instil Bio | Phase 1 |
| Unknown | A Single-arm Clinical Trial of IMGN853 in Chinese Adult Patients With Platinum-resistant, Epithelial Ovarian C NCT05622890 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Phase 3 |
| Completed | Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers NCT05483933 | Shattuck Labs, Inc. | Phase 1 |
| Unknown | A Study to Explore Pamiparib Treatment in Epithelial Ovarian Cancer After Prior PARP Inhibitor Exposure NCT05489926 | Zhejiang Cancer Hospital | Phase 2 |
| Terminated | Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer NCT05261490 | Pfizer | Phase 1 / Phase 2 |
| Recruiting | Tinzaparin And Biomarkers After Neoadjuvant Treatment of Ovarian Cancer NCT05284552 | University Hospital, Linkoeping | Phase 2 |
| Recruiting | A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE) NCT05429970 | Memorial Sloan Kettering Cancer Center | N/A |
| Unknown | A Phase II Trial to Explore Niraparib and Anlotinib Maintenance Retreatment in Platinum-Sensitive Recurrent Ov NCT05385068 | Peking Union Medical College Hospital | Phase 2 |
| Terminated | [18F]Fluoro-PEG-folate PET/CT Imaging in Epithelial Ovarian Cancer NCT05215496 | Lioe-Fee de Geus-Oei, MD PhD | Phase 1 |
| Recruiting | WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC NCT04644289 | AGO Research GmbH | Phase 2 |
| Recruiting | A Study of NI-1801 in Patients with Mesothelin Expressing Solid Cancers NCT05403554 | Light Chain Bioscience - Novimmune SA | Phase 1 |
| Completed | A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors NCT05293496 | MacroGenics | Phase 1 |
| Active Not Recruiting | CRS & HIPEC for Platinum-Resistant Recurrent Ovarian Cancer (KOV-02R, RECOVER) NCT05316181 | National Cancer Center, Korea | Phase 3 |
| Unknown | HRD and Resistance to PAPPi in EOC Patients NCT05310370 | Lei Li | — |
| Unknown | Chromosomal Instability in Ovarian Cancer NCT05310357 | Lei Li | — |
| Recruiting | Survival Effect of Hepato-celiac Lymphadenectomy In Primary or Relapsed Ovarian Cancer NCT05236686 | Shanghai Gynecologic Oncology Group | N/A |
| Unknown | Vitamin D and Pre Cachexia and Cancer Cachexia in Epithelial Ovarian Cancer NCT04864431 | Indonesia University | N/A |
| Unknown | PARP Inhibitor Oral Maintenance in Low-Risk Ovarian Cancer NCT05187208 | Seoul National University Hospital | Phase 4 |
| Active Not Recruiting | A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies NCT05199272 | 23andMe, Inc. | Phase 1 / Phase 2 |
| Unknown | Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOC NCT04983550 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 2 |
| Unknown | Individualized Health Management of Epithelial Ovarian Cancer: A Retrospective Study NCT06085456 | RenJi Hospital | — |
| Unknown | Real-world Study of Niraparib Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer NCT04986371 | Ling-Ying Wu | — |
| Unknown | A Study of Oral Gimatecan in Platinum-Resistant Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer NCT04846842 | Lee's Pharmaceutical Limited | Phase 2 |
| Withdrawn | Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal, NCT03607955 | Washington University School of Medicine | Phase 1 |
| Completed | Study of XB002 in Subjects With Solid Tumors (JEWEL-101) NCT04925284 | Exelixis | Phase 1 |
| Recruiting | PET Imaging of Solid Tumors by a Novel Tracer, 68Ga-FAPI NCT05172310 | Karolinska University Hospital | Phase 1 |
| Active Not Recruiting | Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors NCT04902872 | Cybrexa Therapeutics | Phase 1 / Phase 2 |
| Active Not Recruiting | Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Express NCT04802876 | SOLTI Breast Cancer Research Group | Phase 2 |
| Completed | CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib NCT04676334 | pharmaand GmbH | Phase 3 |
| Active Not Recruiting | TH1902 in Patients With Advanced Solid Tumors NCT04706962 | Theratechnologies | Phase 1 |
| Active Not Recruiting | The INFLUENCE of Cytoreduction on PRO in EOC NCT03268876 | Haukeland University Hospital | — |
| Recruiting | Rectosigmoid Resection vs Seromuscular Tumor Shaving in Ovarian Cancer Surgery NCT04665635 | Cukurova University | N/A |
| Terminated | Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101) NCT04726332 | Exelixis | Phase 1 |
| Active Not Recruiting | Phase I Study of Autologous CAR T-Cells Targeting the B7-H3 Antigen in Recurrent Epithelial Ovarian NCT04670068 | UNC Lineberger Comprehensive Cancer Center | Phase 1 |
| Recruiting | Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignanc NCT04282044 | BioEclipse Therapeutics | Phase 1 |
| Not Yet Recruiting | Stratified Evaluation of PDS and NACT-IDS in Ovarian Cancer (FOCUS) NCT04515602 | Shanghai Gynecologic Oncology Group | Phase 3 |
| Completed | A Study on Association Between HR Genes and the HRD Status in Chinese Epithelial Ovarian Cancer NCT04651920 | Lei Li | — |
| Unknown | A Training Set for the HRD Model in EOC NCT04651933 | Lei Li | — |
| Unknown | Cell-free DNA Methylation for Epithelial Ovarian Cancer NCT04651946 | Lei Li | Phase 2 |
| Recruiting | A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer NCT04516447 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | Phase 1 |
| Terminated | A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-M23, a CAR-T Cell Therapy NCT04562298 | Shanghai East Hospital | Phase 1 |
| Unknown | Clinical Trial of Chemotherapy, Oregovomab and Nivolumab in Patients With Epithelial Cancer of Ovarian, Tubal NCT04620954 | National Cancer Centre, Singapore | Phase 1 / Phase 2 |
| Completed | Niraparib as Maintenance Therapy in Patients With Platinum Sensitive Recurrent Ovarian Cancer NCT04546373 | Grupo Español de Investigación en Cáncer de Ovario | — |
| Recruiting | Determining Prognostic Immune Markers in Patients With Ovarian Cancer NCT03862677 | Leiden University Medical Center | — |
| Terminated | PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platin NCT04493619 | Opna Bio LLC | Phase 1 / Phase 2 |
| Unknown | 68Ga-FAPI-04 and 18F-FDG PET/CT in Patients With Epithelial Ovarian Cancer: Compared With Histological Finding NCT04504110 | Peking Union Medical College Hospital | Phase 2 |
| Unknown | A Randomized Prospective Trail of HIPEC in Recurrent Ovarian Cancer Patients With HRR Mutation NCT04473339 | CAI Hongbing | Phase 3 |
| Completed | Analysis of the Clinical Experience With Rucaparib in the Rucaparib Access Program (RAP) in Spain - A GEICO St NCT04539327 | Grupo Español de Investigación en Cáncer de Ovario | — |
| Completed | A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Pe NCT04296890 | ImmunoGen, Inc. | Phase 3 |
| Terminated | Efficacy of Letrozole in Recurrent Ovarian Cancer NCT04421547 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Phase 3 |
| Recruiting | Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven NCT04429542 | Bicara Therapeutics | Phase 1 |
| Unknown | Translational Analysis In Longitudinal Series of Ovarian Cancer ORganoids NCT04555473 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | — |
| Recruiting | Platino-resistance in Ovarian Cancer NCT03954171 | Institut Claudius Regaud | N/A |
| Active Not Recruiting | Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (K NCT04152499 | Klus Pharma Inc. | Phase 1 / Phase 2 |
| Completed | A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Adv NCT04209855 | AbbVie | Phase 3 |
| Unknown | Genetic Mutation in Epithelial Ovarian Cancer NCT04191252 | Lei Li | — |
| Unknown | Homologous Recombination Deficiency Status in Epithelial Ovarian Cancer NCT04190667 | Lei Li | — |
| Completed | Genomic BRCA and Extensive ovArian Cancer Testing NCT04027868 | ARCAGY/ GINECO GROUP | — |
| Completed | The Real World Efficacy and Safety of Niraparib in Korean Women With Primary and Recurrent Epithelial Ovarian NCT06086665 | Asan Medical Center | — |
| Unknown | Development of a Biomarker to Predict the Efficacy of Anti-angiogenic Therapy in Ovarian Cancer NCT05874115 | Centro di Riferimento Oncologico - Aviano | — |
| Unknown | Efficacy of HIPEC in the Treatment of Advanced-Stage Epithelial Ovarian Cancer After Cytoreductive Surgery NCT03373058 | Affiliated Cancer Hospital & Institute of Guangzhou Medical University | Phase 3 |
| Completed | Diagnosis of Epithelial Ovarian Cancer Using Ovarian Cancer Score (OCS) Test NCT06366997 | Chongqing University Cancer Hospital | — |
| Unknown | Granulocyte Colony Stimulating Factor for for the Prevention of Febrile Neutropenia in Epithelial Ovarian Canc NCT04101760 | Lei Li | Phase 3 |
| Terminated | A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES) NCT03824704 | pharmaand GmbH | Phase 2 |
| Terminated | Evaluation and Treatment of Iron Deficiency in Ovarian Cancer Patients NCT03933813 | University of Wisconsin, Madison | Phase 1 / Phase 2 |
| Completed | A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tum NCT03849469 | Xencor, Inc. | Phase 1 |
| Unknown | Selecting Chemotherapy With High-throughput Drug Screen Assay Using Patient Derived Organoids in Patients With NCT04279509 | National University Hospital, Singapore | N/A |
| Active Not Recruiting | A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors NCT03872947 | Toray Industries, Inc | Phase 1 |
| Unknown | Study of Anti-Mesothelin Car NK Cells in Epithelial Ovarian Cancer NCT03692637 | Allife Medical Science and Technology Co., Ltd. | EARLY_Phase 1 |
| Unknown | Tri Association in Patient With Advanced Epithelial Ovarian Cancer in Relapse NCT04015739 | ARCAGY/ GINECO GROUP | Phase 2 |
| Completed | Exploration of DNA Methylation as a Marker for Early Detection of High Grade Serous Epithelial Ovarian Cancer NCT03622385 | Baylor Research Institute | — |
| Unknown | A Genomic Analysis of Evolution of Epithelia Ovarian Tumors NCT03742388 | Lei Li | — |
| Unknown | Long-acting G-CSF for Febrile Neutropenia NCT03740464 | Lei Li | Phase 3 |
| Unknown | A Multi-omics Study of Epithelial Ovarian Cancer NCT03742856 | Lei Li | — |
| Active Not Recruiting | Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2) NCT03393884 | Imunon | Phase 1 / Phase 2 |
| Completed | Microscopic Peritoneal Metastases After Complete Macroscopic Cytoreductive Surgery for Epithelial Ovarian Canc NCT03754569 | Assistance Publique - Hôpitaux de Paris | N/A |
| Active Not Recruiting | A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Respo NCT03522246 | pharmaand GmbH | Phase 3 |
| Unknown | Efficacy of HIPEC as NACT and Postoperative Chemotherapy in the Treatment of Advanced-Stage Epithelial Ovarian NCT03180177 | Shu-Zhong Cui | Phase 3 |
| Unknown | Heated Intraperitoneal Chemotherapy in Primary Ovarian Cancer Patients NCT03321188 | Andrea Jewell | Phase 2 |
| Completed | Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal Int NCT03213964 | Masonic Cancer Center, University of Minnesota | Phase 1 |
| Unknown | Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced a NCT03371693 | Zhongnan Hospital | Phase 3 |
| Completed | Plasma ctDNA Detection in Diagnosis of Epithelial Ovarian Cancer. NCT03155451 | RenJi Hospital | — |
| Completed | A Study to Examine Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer. NCT03106987 | AstraZeneca | Phase 3 |
| Completed | Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab NCT03093155 | Yale University | Phase 2 |
| Unknown | Overcoming Chemoresistance in Advanced Ovarian Cancer Via Targeting Hypoxia NCT04001023 | Turku University Hospital | N/A |
| Completed | ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Ca NCT02855944 | pharmaand GmbH | Phase 3 |
| Terminated | Phase Ib/IIa Trial to Evaluate Oregovomab and Nivolumab in Epithelial Cancer of Ovarian, Tubal or Peritoneal O NCT03100006 | National Cancer Centre, Singapore | Phase 1 / Phase 2 |
| Completed | Ovarian Tumor Biopsies to Study Response to Treatments NCT02952521 | University Health Network, Toronto | — |
| Terminated | Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Epithelial Ovarian Cancer (EOC). NCT02834975 | University of Miami | Phase 2 |
| Terminated | Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer NCT02900560 | Translational Research in Oncology | Phase 2 |
| Completed | Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian Cancer NCT02915523 | Syndax Pharmaceuticals | Phase 1 / Phase 2 |
| Terminated | HKT288 in Solid Tumors, Including Epithelial Ovarian Cancer and Renal Cell Carcinoma NCT02947152 | Novartis Pharmaceuticals | Phase 1 |
| Terminated | Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defac NCT02943317 | Verastem, Inc. | Phase 1 |
| Withdrawn | HIPEC After Secondary Cytoreductive Operation in Patients With Platinum-sensitive Recurrence of Ovarian Carcin NCT02487849 | Krankenhaus Barmherzige Schwestern Linz | Phase 2 |
| Active Not Recruiting | Study of Upfront Surgery Versus Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer (SUNNY) NCT02859038 | Shanghai Gynecologic Oncology Group | Phase 3 |
| Completed | A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers NCT02728830 | AA Secord | EARLY_Phase 1 |
| Active Not Recruiting | Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors NCT02644369 | University Health Network, Toronto | Phase 2 |
| Completed | Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubic NCT02606305 | ImmunoGen, Inc. | Phase 1 / Phase 2 |
| Completed | A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor ( NCT02631876 | ImmunoGen, Inc. | Phase 3 |
| Completed | LCC-CARIS-01: Molecular Profiling in Gynaecological Cancer NCT02668913 | Geoff Hall | N/A |
| Completed | A Study of Long-Term Responders on Olaparib NCT02489058 | University Health Network, Toronto | — |
| Completed | Study of Metformin With Carboplatin/Paclitaxel Chemotherapy in Patients With Advanced Ovarian Cancer NCT02312661 | University Medical Center Groningen | Phase 1 |
| Completed | Study of Safety & Biological Activity of IP IMNN-001 (also Known As GEN-1) with Neoadjuvant Chemo in Ovarian C NCT02480374 | Imunon | Phase 1 |
| Unknown | Total/Subtotal Colectomy in Ovarian Cancer NCT02595021 | Shanghai Gynecologic Oncology Group | Phase 2 |
| Completed | Mirena® IUD's Effect on Fallopian Tube Fimbriae and Ovarian Cortical Inclusion Cyst Cell Proliferation NCT02477202 | Memorial Sloan Kettering Cancer Center | N/A |
| Completed | Flaxseed as Maintenance Therapy for Ovarian Cancer Patients in Remission NCT02324439 | Southern Illinois University | Phase 1 |
| Completed | Live After an Epithelial Ovarian Cancer: Multidisciplinary Assessment of Effects and Long-term Remission in Pa NCT02323568 | Centre Francois Baclesse | N/A |
| Terminated | GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer NCT02012192 | Medical University Innsbruck | Phase 1 / Phase 2 |
| Completed | CART-meso in Mesothelin Expressing Cancers NCT02159716 | University of Pennsylvania | Phase 1 |
| Active Not Recruiting | HOT: HIPEC in Ovarian Cancer as Initial Treatment NCT02124421 | Mercy Medical Center | Phase 2 |
| Completed | Postoperative Adjuvant Chemotherapy With Bevacizumab and Maintenance Bevacizumab After Neoadjuvant Chemotherap NCT02022917 | Chang Gung Memorial Hospital | Phase 2 |
| Completed | A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian T NCT01891344 | pharmaand GmbH | Phase 2 |
| Completed | Phase 1b Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Canc NCT03332576 | ImmunoVaccine Technologies, Inc. (IMV Inc.) | Phase 1 |
| Completed | Safety, Tolerability and Pharmacokinetics of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With NCT02728492 | NewVac LLC | Phase 1 |
| Terminated | A Study to Compare CAELYX With Topotecan HCL in Patients With Recurrent Epithelial Ovarian Carcinoma Following NCT01840943 | Xian-Janssen Pharmaceutical Ltd. | Phase 3 |
| Completed | First Line Ovarian Cancer Treatment - Cohort Study NCT01832415 | ARCAGY/ GINECO GROUP | — |
| Completed | To Evaluate Plasmajet in Achieving Complete Cytoreduction of Advanced EOC- Initial Feasibility Study NCT02376231 | Dr Thumuluru Kavitha Madhuri | N/A |
| Completed | VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian NCT01666444 | Celgene | Phase 2 |
| Unknown | Study on Neutropenia Induced by Adjuvant Paclitaxel/Carboplatin Chemotherapy in Patients With Epithelial Ovari NCT01680575 | Asan Medical Center | — |
| Terminated | Birinapant for Advanced Ovarian, Fallopian Tube, and Peritoneal Cancer NCT01681368 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Phase III Trial of Stage I Ovarian Cancer After Surgery NCT04063527 | Japanese Gynecologic Oncology Group | Phase 3 |
| Completed | A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer NCT01649336 | Array Biopharma, now a wholly owned subsidiary of Pfizer | Phase 1 |
| Completed | A Study LY2228820 for Recurrent Ovarian Cancer NCT01663857 | Eli Lilly and Company | Phase 1 / Phase 2 |
| Completed | Research on Nutritional Risk Indexes and Inflammatory Indicators in Postoperative Complications and Prognosis NCT06483399 | Qinglei Gao | — |
| Terminated | Cvac as Maintenance Treatment in Patients With Epithelial Ovarian Cancer in Complete Remission Following First NCT01521143 | Prima BioMed Ltd | Phase 2 |
| Unknown | Hyperthermic Intraperitoneal Chemotherapy With Paclitaxel in Advanced Ovarian Cancer NCT02681432 | PEDRO VILLAREJO CAMPOS | Phase 3 |
| Completed | Ovarian Cancer Vaccine for Patients Who Have Progressed During the CAN-003 Study NCT01617629 | Prima BioMed Ltd | Phase 2 |
| Completed | A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers NCT01447706 | Merrimack Pharmaceuticals | Phase 2 |
| Completed | Acute Normovolemic Hemodilution in Patients Undergoing Cytoreductive Surgery for Advanced Ovarian Cancer NCT01442051 | Memorial Sloan Kettering Cancer Center | N/A |
| Completed | FES-PET to Determine ER-expression in Epithelial Ovarian Cancer NCT01439490 | University Medical Center Groningen | Phase 2 |
| Completed | Surgical Trial Comparing LIGASURE Assisted Recto-Sigmoid Resection and Omentectomy Compared to Stand NCT01549925 | University of Utah | N/A |
| Completed | Belotecan Versus Topotecan for Recurrent Ovarian Cancer: A Randomized, Open-label, Parallel-group Phase IIb Tr NCT01630018 | Chong Kun Dang Pharmaceutical | Phase 2 |
| Completed | Phase I/II Study of Pazopanib and Cyclophosphamide in Patients With Platinum-resistant Recurrent Ovarian Cance NCT01238770 | Priv.-Doz. Dr. med. Joachim Rom | Phase 1 / Phase 2 |
| Terminated | Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer NCT01202890 | New Mexico Cancer Research Alliance | Phase 1 |
| Completed | Ovarian Cancer Vaccine for Patients in Remission NCT01068509 | Prima BioMed Ltd | Phase 2 |
| Completed | Study With Wee-1 Inhibitor AZD1775 (MK-1775) and Carboplatin to Treat p53 Mutated Refractory and Resistant Ova NCT01164995 | The Netherlands Cancer Institute | Phase 2 |
| Completed | Neoadjuvant Therapy for Ovarian Cancer NCT01146795 | Jason D. Wright | Phase 2 |
| Completed | Intraperitoneal Therapy For Ovarian Cancer With Carboplatin Trial NCT01506856 | Gynecologic Oncology Trial & Investigation Consortium | Phase 2 / Phase 3 |
| Terminated | Seprafilm™ for the Prevention of Intraperitoneal Adhesions and Improved Delivery of Therapy in Women Undergoin NCT01095367 | University of British Columbia | N/A |
| Completed | Intraoperative Hyperthermic Intraperitoneal Chemotherapy With Ovarian Cancer NCT01091636 | National Cancer Center, Korea | Phase 2 / Phase 3 |
| Terminated | An Open Label Extension Study of the Efficacy of MORAb-003 NCT01018563 | Morphotek | Phase 2 |
| Withdrawn | Study to Assess Safety and Tolerability of AZD0530 in Combination With Carboplatin and Paclitaxel NCT01000896 | AstraZeneca | Phase 1 |
| Completed | Safety Study of Farletuzumab, Carboplatin and Pegylated Liposomal Doxorubicin (PLD) to Treat Platinum-sensitiv NCT01004380 | Morphotek | Phase 1 |
| Completed | A Trial Using Novel Markers to Predict Malignancy in Elevated-Risk Women NCT01121640 | Fred Hutchinson Cancer Center | N/A |
| Active Not Recruiting | Epithelial Ovarian Cancer- Staging and Response to Chemotherapy Evaluated by PET/CT NCT01276574 | Turku University Hospital | — |
| Terminated | A Trial of Intravenous Denileukin Diftitox Plus Subcutaneous Pegylated IFNα-2A in Stage III or IV Ovarian Canc NCT01773889 | The University of Texas Health Science Center at San Antonio | Phase 2 |
| Completed | Panitumumab and Pegylated Liposomal Doxorubicin for Platinum-Resistant Epithelial Ovarian Cancer With KRAS Wil NCT00861120 | Vejle Hospital | Phase 2 |
| Completed | Study of Paclitaxel in Patients With Ovarian Cancer NCT00989131 | Oasmia Pharmaceutical AB | Phase 3 |
| Completed | Early Post-Operative Enteral Feeding in Patients With Advanced Epithelial Ovarian Cancer NCT00850772 | Queensland Centre for Gynaecological Cancer | Phase 3 |
| Completed | Prevention of Ovarian Cancer in Women Participating in Mammography NCT01851109 | Fred Hutchinson Cancer Center | N/A |
| Completed | Phase 1 Study of NY-ESO-1 Overlapping Peptides in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Ca NCT00616941 | Ludwig Institute for Cancer Research | Phase 1 |
| Terminated | Hyperthermic Intraoperative Intraperitoneal Chemotherapy of Recurrent Ovarian Cancer - A Feasibility Study NCT00968799 | Cantonal Hospital of St. Gallen | N/A |
| Completed | Phase II Study of the Trifunctional Antibody Catumaxomab Administered Intra- and Postoperatively in Patients W NCT00563836 | Neovii Biotech | Phase 2 |
| Completed | Feasibility Study of Pazopanib in Combination With Chemotherapy in Gynaecological Tumors NCT00561795 | GlaxoSmithKline | Phase 2 |
| Completed | A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian Cancer NCT00880360 | The University of Texas Health Science Center at San Antonio | Phase 2 |
| Terminated | Intraperitoneal (IP) Cisplatin Given With Paclitaxel to Treat Epithelial Ovarian Cancer NCT00889733 | University Health Network, Toronto | Phase 1 / Phase 2 |
| Completed | Bevacizumab With Abraxane in Patients With Recurrent Ovarian/ Peritoneal Cancer NCT00407563 | Accelerated Community Oncology Research Network | Phase 2 |
| Completed | Safety and Efficacy Clinical Study of SNS-595 in Patients With Platinum-Resistant Ovarian Cancer NCT00408603 | Sunesis Pharmaceuticals | Phase 2 |
| Completed | Comparison of Paclitaxel/Carboplatin and Lonafarnib to Paclitaxel/Carboplatin for First-line Treatment of Ovar NCT00281515 | AGO Study Group | Phase 2 |
| Completed | Predictors of Relapse of Ovarian, Peritoneal, and Fallopian Tube Cancers NCT00086567 | National Cancer Institute (NCI) | — |
| Completed | Cisplatin Induction With Paclitaxel Consolidation for Stage III-IV Epithelial Ovarian and Primary Peritoneal C NCT00314678 | John P. Fruehauf | Phase 2 |
| Completed | A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse T NCT00421889 | Valerio Therapeutics | Phase 1 / Phase 2 |
| Completed | Multi-national, Randomized, Phase III, GCIG Intergroup Study Comparing Pegylated Liposomal Doxorubicin (CAELYX NCT00538603 | King Faisal Specialist Hospital & Research Center | N/A |
| Completed | Safety, Tolerability and Pharmacokinetics of MORAb-003 in Subjects With Advanced Ovarian Cancer NCT00428766 | Morphotek | Phase 1 |
| Completed | Women Surviving Ovarian Cancer NCT00596349 | Memorial Sloan Kettering Cancer Center | — |
| Completed | Pathogenic Variants in Homologous Recombination Repair Genes in Patients With Epithelial Ovarian Cancer NCT04716374 | Hellenic Cooperative Oncology Group | — |
| Completed | Treatment of Paclitaxel Plus Carboplatin Followed by Gemcitabine Plus Carboplatin for Patients With Epithelial NCT00490711 | Eli Lilly and Company | Phase 2 |
| Completed | Trial of Tri-weekly TJ Versus Weekly TJ for Stage II-IV Mullerian Carcinoma NCT00226915 | Japanese Gynecologic Oncology Group | Phase 3 |